Doug Johnson
Senior Director Biogen
Seminars
Wednesday 21st October 2026
Selective Covalent Targeting in Drug Discovery: Lessons from FAAH, JAK3, & BTK Toward Safer Therapeutics
1:30 pm
- Case-study–driven insights from FAAH, JAK3, and BTK programs highlighting key learnings in covalent inhibitor discovery
- Defining when covalent targeting adds value across enzyme and kinase classes
- Linking hepatic selectivity to safety, with a focus on DILI risk and mechanistic understanding
